focus -WSS

focus

author：hotspot 2025-09-27 11:58:22 - browse：9319

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Juul documents reveal insider tactics on political lobbying

leisure time

WSS

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Here’s what’s in the FDA plan to include pregnant women in clinical trials

In same hospitals, Black patients receive fewer opioids than white patients

A biotech analyst on neuroscience, placebo effect, not over

Juul documents reveal insider tactics on political lobbying

Bernie Sanders gets little from pharma CEOs on drug prices

entertainment

focus

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Friends ask where James Watson's attitudes about race came from

Medical records are filled with copy

A biotech analyst on neuroscience, placebo effect, not over

Jerome Adams on the need for new antivirals for Covid

Anavex keeps shifting the goalposts in its clinical trials

Sports medicine is finally prioritizing gender equality

STAT Boddities: What happens to the brain when we get scared?

How one medical school became remarkably diverse

What to know about Virgin Galactic's 1st mission taking paying customers to space

focus

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

A biotech analyst on neuroscience, placebo effect, not over

Bernie Sanders gets little from pharma CEOs on drug prices

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Friends ask where James Watson's attitudes about race came from

Why don't Americans have at

hotspot

leisure time

hotspot

hotspot